Deep Dive: These are the only 7 stocks in the S&P 500 that rose while the market plunged

This post was originally published on this site

In any market environment, there are exceptions to the trend. But there aren’t many this time.

Since the S&P 500 SPX, -3.96%  hit its last closing record on Feb. 19, the index has skidded 12% — and only seven of the component stocks haven’t declined through the close on Feb. 27. See the list below.

Before you get there, here’s a list of stocks in the index that took the worst beatings, along with a summary of how the 11 sectors performed.

It might surprise you that Tesla TSLA, -9.43%  isn’t on that list of decliners, but the electric car maker hasn’t yet met the requirements to be included in the S&P 500. Before the outbreak of the coronavirus strain known as COVID-19, it appeared likely to be added to the index by the end of 2020. Tesla’s stock was down nearly $100 (13%) on Feb. 27 to close at $679. The stock was down $238 (26%) since it set a closing record of $917.42 on Feb. 19.

Read: Tesla’s stock tumbles toward biggest-ever weekly drop

So here are the exceptions — seven S&P 500 stocks that rose in price between Feb. 19 and Feb. 27:

Company Ticker Industry Price change since Feb. 19 Price change – 2020 Decline from 52-week high Price change – 2019
Gilead Sciences Inc. GILD, -4.51% Biotechnology 7.9% 11.8% -7.9% 3.9%
Regeneron Pharmaceuticals Inc. REGN, -1.72% Biotechnology 7.7% 14.9% -8.2% 0.5%
Clorox Co. CLX, -4.27% Household/Personal Care 2.3% 9.9% -3.1% -0.4%
E-Trade Financial Corp. ETFC, -3.70% Investment Banks/Brokers 2.3% 1.3% -19.8% 3.4%
CME Group Inc. Class A CME, -4.22% Investment Banks/Brokers 1.4% 4.8% -6.6% 6.7%
Newmont Corp. NEM, -7.26% Precious Metals 0.8% 7.1% -9.4% 25.4%
Cboe Global Markets Inc. CBOE, -3.94% Investment Banks/Brokers 0.7% 1.0% -5.2% 22.7%
Source: FactSet

You can click the tickers for more about each company.

• Gilead Sciences GILD, -4.51%  has announced two Phase 3 clinical studies to measure the effectiveness of its Remdesivir medication in countering COVID-19 infections. The company’s Feb. 26 press release has more details. Jefferies analyst Michael Yee rates Gilead a “buy,” but wrote in a note to clients on Feb. 26 that although he is pleased that fighting the virus is a ‘very high priority” for Gilead’s management, “the financial implications are modest (pricing, one-time use, no tail).”

• Regeneron Pharmaceuticals REGN, -1.72%  ws upgraded to a “Buy” by Jefferies analyst Biren Amin on Feb. 25, because he believes competitive risk to the company’s Eylea macular degeneration therapy has been minimized because of safety concerns over Novartis AG’s NVS, -3.09% NOVN, -4.33%  Beovu medication.

• Clorox CLX, -4.27%  is an obvious defensive stock during a time when people are concerned about the spread of a deadly virus and reaching for bleach. But Charles Lemonides, founder of ValueWorks LLC in New York, argued that for long-term investors, Clorox’s high valuation to earnings actually makes it a risky stock.

• E-Trade Financial ETFC, -3.70%  agreed on Feb. 20 to be acquired by Morgan Stanley MS, -3.59%  in an all-stock deal valued at $58.74 a share at that time. E-Trade’s shares closed at $45.95 Thursday. The deal calls for an exchange of 1.0432 Morgan Stanley shares for every E-Trade share. Morgan Stanley’s shares closed at $45.41 on Feb. 27, so based on those numbers, E-Trade’s takeout price would be $47.37.

Create an email alert for Philip van Doorn’s Deep Dive columns here.

Add Comment